The Regulator
$209.40 a month: that is what Medicare’s standard Part B premium will cost in 2027, $6.50 more than this year’s $202.90. The Centers for Medicare & Medicaid Services (CMS) filed the annual notice for public inspection on November 17, and it is scheduled for formal Federal Register publication November 19. The notice sets the 2027 Part B deductible at $292, up from $283, and the monthly premium rise works out to 3.2 percent. Higher earners pay more through income-related adjustments that begin at $112,000 for an individual tax return and $224,000 for a joint return. The premium for people who keep Part B coverage of immunosuppressive drugs after a kidney transplant will be $125.70. Who it hits: every Part B enrollee, plus Medigap and employer retiree plans that price off these amounts. At $209.40, the standard premium is $2,512.80 a year, or $78 more than 2026. All amounts take effect January 1, 2027. Confidence: High, because the figures come from CMS’s own notice. Sources: CMS Part B premium notice, Federal Register public inspection document 2026-23601.
CMS proposed a sweeping fraud rule across Medicare, Medicaid and the ACA marketplace, and puts the rule’s own cost at $379 million over ten years. The proposed rule, titled “Comprehensive Regulations to Uncover Suspicious Healthcare” (CMS-6098-P), was filed for public inspection November 16 and is also scheduled to publish November 19. It would tighten provider enrollment and identity checks, speed reporting of credible allegations of fraud that trigger Medicaid payment suspensions, and require every provider that bills a Medicare Advantage plan to enroll in Original Medicare, including out-of-network providers. CMS says the quantified provisions cost about $379 million from 2027 to 2036 and would move more than $90 billion in transfers between the federal government, states and private entities. For Medicare Advantage risk adjustment audits, which check plan-reported diagnoses against medical records, CMS estimates extrapolated recoveries of about $9 billion per audit year beginning with payment year 2018 audits. Who it hits: Medicare Advantage plans and their contracted providers, state Medicaid agencies, and any supplier with a revocation history. Comments are due 60 days after publication, under docket CMS-2026-0826. Confidence: High on the proposal’s contents and CMS’s stated figures; Low on how many of the $90 billion in transfers would actually materialize, since CMS states no timeline. Sources: CMS proposed rule, Federal Register public inspection document 2026-23461.
Medicare’s 2027 hospital deductible will be $1,776, up $40, and a hospital stay past day 60 will cost $444 a day. Two companion CMS notices, also scheduled for Federal Register publication November 19, set the Part A (hospital insurance) cost-sharing amounts. The inpatient deductible rises from $1,736. Coinsurance is $444 a day for days 61 to 90 of a hospital stay, $888 for each lifetime reserve day, and $222 a day for days 21 to 100 in a skilled nursing facility. The separate Part A premium for people who lack enough work history to qualify for free coverage will be $597 a month, or $328 for certain others. Who it hits: Medicare patients with long stays, and the Medigap insurers that cover these amounts. Confidence: High. Sources: CMS inpatient deductible notice, public inspection document 2026-23603, CMS Part A premium notice, public inspection document 2026-23604.
FDA launched a program that lets drug makers hand foreign regulators its lightly redacted approval files, starting with HIV drugs. The Food and Drug Administration (FDA) announced the Global Reliance Disclosure Program November 17. It lets applicants share minimally redacted FDA review packages with health authorities abroad so those agencies can rely on FDA’s findings instead of repeating the review. It began October 30 with a President’s Emergency Plan for AIDS Relief (PEPFAR) tentative approval for lenacapavir and now covers only PEPFAR tentative approvals. FDA says it intends to expand it in January 2027 to all new molecular entity drug applications and new biologics license applications. Applicants must request participation within 10 calendar days of approval. Who it hits: drug makers filing in multiple countries, and foreign regulators with limited review capacity. FDA gives no cost or time-saving figure. Confidence: High on the program’s terms. Sources: FDA news release.
FDA approved Lembaz, the first therapy shown to reduce the risk of death in infantile-onset Niemann-Pick disease type C. The agency approved adrabetadex injection November 17 for patients weighing at least 7 kilograms whose neurological symptoms began before age 6. FDA says treated patients had a 55 percent lower risk of death than a matched external control group, with median survival of 8.5 years versus 4.9. The evidence is 36 patients across three studies and an expanded access program, compared against external controls rather than a randomized placebo group. A provider gives the drug into the spinal canal every two weeks. Who it hits: families of children with a disease affecting about 1 in 150,000 people, and payers that will price a rare-disease injection. FDA’s release gives no price. Confidence: High on the approval and survival figures; Low on cost, which is not yet public. Sources: FDA news release.
The Indian Health Service set its 2027 catastrophic-case fund threshold at $20,258, up 3.2 percent. A notice published in today’s Federal Register sets the threshold for fiscal year 2027 requests to the Catastrophic Health Emergency Fund, which covers extraordinary medical costs from disasters and catastrophic illness for people the Service is responsible for. The threshold rises from $19,630 under a formula tied to the medical care category of the Consumer Price Index. Who it hits: tribal and Indian Health Service facilities that file requests. Confidence: High. Sources: Federal Register notice, 91 FR 74178.
Quiet note: today’s other health filings in the Federal Register were meeting and information-collection notices, an FDA drug-approval-withdrawal proposal for Salerno Pharmaceuticals’ Flolipid suspension, and an FDA determination on BROMFED-DM syrup. We did not find a verified state-level action dated in the last 48 hours, so there is no state item today.
Free. One email a day at 6pm your time, or one summary every Friday. Switch or stop anytime.